Feature

Sequencing Therapies in Non-Hodgkin Lymphomas

Share

At JADPRO Live 2025, F. Brianne Buchanan, PA-C, and Tatjana Grgic, PharmD, provided insights on selecting and sequencing therapies for relapsed/refractory B-cell non-Hodgkin lymphomas. Emphasis was placed on Bruton tyrosine kinase (BTK) inhibitors, bispecific antibodies, and CAR T-cell therapies. Challenges include managing drug interactions, monitoring for toxicity like CRS and ICANS, and considering patient-specific factors. The talk highlighted logistical considerations and the importance of palliative care to enhance patients' quality of life throughout treatment.

Original Source(s)

Sequencing Therapies in Non-Hodgkin Lymphomas

  • by F. Brianne Buchanan, PA-C, Tatjana Grgic, PharmD, BCOP, CPP

  • February 27, 2026

  • 9 min

Related Content

Novel Therapies and Multidisciplinary Strategies in Metastatic Triple-Positive Breast Cancer

United in Care at JADPRO Live 2025

Management of Ocular Toxicity in Patients Receiving Belantamab Mafodotin

While significant strides have been made in the treatment of multiple myeloma, treatment options remain limited and definite, and most patients ultimately succumb to their disease. The urgency for mor...